Form 4: CalciMedica CBO Boosts Stake with Share Purchase

CalciMedica's Chief Business Officer, Eric W. Roberts, acquired 3,400 shares of common stock, signaling confidence in the company.

Summary

• Eric W. Roberts, who serves as Chief Business Officer, Director, and a 10% Owner of CalciMedica, Inc. (CALC), acquired additional shares of the company's common stock.
• The transaction involved the purchase of 3,400 shares of common stock on September 15, 2025.
• The shares were acquired at a weighted average price of $2.6779 per share, with individual purchase prices ranging between $2.65 and $2.70.
• Following this transaction, Roberts' beneficial ownership includes 81,650 shares indirectly via FMTC Custodian Roth IRA, 179,706 shares directly, 49,894 shares indirectly via Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares indirectly via IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares indirectly via Valence Investments SPV IV, LLC, 66,228 shares indirectly via Valence Investments SPV V, LLC, and 316,109 shares indirectly via Valence Investments SPV VI, LLC, totaling 1,061,237 shares.

Sentiment

Score: 8

Explanation: The purchase of shares by a high-ranking insider, who is also a director and 10% owner, is a strong positive signal, indicating management's belief in the company's value and future performance.

Positives

• A key insider, Eric W. Roberts, holding significant roles as Chief Business Officer, Director, and a 10% Owner, purchased additional shares, indicating strong confidence in the company's future prospects and current valuation.
• The acquisition of 3,400 shares at an average price of $2.6779 represents a direct financial commitment from a high-ranking member of management.

Future Outlook

NA

Industry Context

Insider buying in the biotechnology sector can often signal management's belief in the company's pipeline, upcoming clinical trial results, or potential regulatory milestones, which are critical value drivers for pharmaceutical and biotech firms like CalciMedica.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's confidence, potentially leading to increased investor interest and positive sentiment.
• Employees might perceive this as a sign of stability and positive future outlook for the company.

Key Dates

Recommendation

The purchase of shares by a key insider, who holds multiple significant roles (CBO, Director, 10% Owner), typically signals strong confidence in the company's current valuation and future growth trajectory. This insider buying suggests that management believes the stock is undervalued or expects positive developments, making it a favorable indicator for potential investors.

Keywords

CalciMedica, CALC, Insider Trading, Form 4, Eric W. Roberts, Share Purchase, Common Stock, Biotechnology, Pharmaceuticals